Pharmacokinetics and dynamics calculator

The ongoing analysis of the patients supports that up to 50% of evaluable patients (patients who have been clinically assessed by the principal investigators at study visits and whose response to a treatment can be measured because enough information has been collected) have achieved the primary study objective. I am encouraged by the clinical data generated to date with intravesical TLD-1433, activated by laser light therapy, as I believe Theralase В®вЂ™s PDT is a viable alternative for the BCG-Unresponsive NMIBC patient population, although significant data is still pending. As a direct result of the success of this initial Study, Theralase В® elected to undertake Study II, which I am happy to report is proceeding well. Indeed, the publication of clinical results in a peer reviewed journal like EUOS validates the quality of the Theralase В® research and the professionalism of the clinical study team, who conducted it. Arkady Mandel M.D., Ph.D., D.Sc., Interim Chief Executive Officer and Chief Scientific Officer of Theralase В® stated, вЂњThe Company is very pleased to share the Study clinical data that has been peer-reviewed and published in EUOS. I am fully supportive of the multi-site Phase II NMIBC clinical study, currently in progress, to further investigate the role of PDT in BCG-Unresponsive NMIBC.вЂќДr. The clinical data that we collected was robust and clinically relevant. Many also failed other investigational therapies prior to being treated with Theralase В®вЂ™s PDT. Patients with BCG-Unresponsive NMIBC are a difficult patient population to treat since they have unfortunately failed the standard of care, BCG. Girish Kulkarni, M.D., Ph.D., lead principal investigator of the Study at the Divisions of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada (вЂњ UHNвЂќ) stated, 'I am delighted that the high-quality research conducted at UHN, in conjunction with Theralase В®, was successful, in this challenging patient population, both for safety and potential efficacy. Study II is currently underway at 5 Clinical Study Sites (вЂњ CSSвЂќ) in Canada and 7 CSSs in the United States, with 41 patients treated to date. In this study, Photo Dynamic Therapy (вЂњ PDTвЂќ) was well tolerated and demonstrated safety and potential efficacy, thus warranting further study.вЂќДЄs a result, the Medical and Scientific Advisory Board (вЂњ MSABвЂќ) unanimously agreed that Theralase В® should further investigate PDT in a multi-site, pivotal Phase II NMIBC Clinical Study (вЂњ Study IIвЂќ). The publication is entitled, вЂњA Phase 1b Clinical Study of Intravesical Photodynamic Therapy in Patients with Bacillus Calmette-GuГ©rinвЂ“unresponsive NonвЂ“muscle-invasive Bladder CancerвЂќ and states, вЂњAlthough limited by the small sample size typically inherent in phase 1 trials, we feel that the photosensitizer TLD-1433 and the delivery device TLC-3200 hold promise for the treatment of NMIBC. An effective therapy that provides a high initial and durable responses remains an unmet need.вЂќ The publication states, вЂњDespite efforts to bring new treatment strategies forward for Bacillus Calmette GuГ©rin (вЂњ BCGвЂќ)-Unresponsive NMIBC, a clear consensus for a standard treatment other than radical cystectomy has yet to be established. The publication can be accessed online at no charge at: EUOS covers research in the urological field, including clinical, basic and translational research. (вЂњ TheralaseвЂќ or the вЂњ CompanyвЂќ) ( TSXV: TLT) ( TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (вЂњ PDCвЂќ) and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that Theralase В®вЂ™s Phase Ib Non-Muscle Invasive Bladder Cancer (вЂњ NMIBCвЂќ) clinical study (вЂњ StudyвЂќ) has been peer reviewed and published in the European Urology Open Science (вЂњ EUOSвЂќ) Journal, Volume 41, July 2022.ДЄccording to EUOSвЂ™s website, EUOS is dedicated to the publication of high quality, innovative research that will benefit patients with urological conditions. TORONTO, J(GLOBE NEWSWIRE) - Theralase В® Technologies Inc.

Pharmacokinetics and dynamics calculator